The Phase I/II Deliver trial sought to establish the impact of DYNE-251 on several mobility-related endpoints, seeing an ...

Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys ...

announced new long-term clinical data from its Phase 1/2 DELIVER trial of DYNE-251 demonstrating unprecedented and sustained functional improvement at the selected registrational dose of 20 mg/kg ...

Dyne Therapeutics (NASDAQ:DYN) on Monday  reported new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating “unprecedented and sustained functional improvement at ...

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for ...

and the potential of DYNE-101 and DYNE-251, and the availability of expedited approval pathways constitute forward-looking statements within the meaning of The Private Securities Litigation Reform ...

and the potential of DYNE-101 and DYNE-251, and the availability of expedited approval pathways constitute forward-looking statements within the meaning of The Private Securities Litigation Reform ...

Piper Sandler maintained an Overweight rating with a $48 target, highlighting promising data from the DYNE-251 trial for Duchenne muscular dystrophy. The company reported sustained benefits in ...

Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation - WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics ...